Evidence map›Paper›PMID 41948925›Full record

ArticleLab on a chip2026

Band-stop microfluidics for high-purity, label-free enrichment of viable cancer cells from whole blood.

Lewis Krzeczkowski, Georgios Nteliopoulos, Simak Ali, Paul Davey, R Charles Coombes, Ali Salehi-Reyhani

Abstract read
In one paragraph

Article in Lab on a chip, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lewis KrzeczkowskiDepartment of Surgery & Cancer, Imperial College London, London, W12 0HS, UK. ali.salehi-reyhani@imperial.ac.uk.
Georgios NteliopoulosDepartment of Surgery & Cancer, Imperial College London, London, W12 0HS, UK. ali.salehi-reyhani@imperial.ac.uk.
Simak AliDepartment of Surgery & Cancer, Imperial College London, London, W12 0HS, UK. ali.salehi-reyhani@imperial.ac.uk.ORCID 0000-0002-1320-0816
Paul DaveyOncology Medicinal Chemistry, R&D AstraZeneca, The Discovery Centre, Biomedical Campus, 1 Francis Crick Avenue, Cambridge, CB2 0AA, UK.
R Charles CoombesDepartment of Surgery & Cancer, Imperial College London, London, W12 0HS, UK. ali.salehi-reyhani@imperial.ac.uk.
Ali Salehi-ReyhaniDepartment of Surgery & Cancer, Imperial College London, London, W12 0HS, UK. ali.salehi-reyhani@imperial.ac.uk.ORCID 0000-0002-1084-2012

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liquid biopsy requires the isolation of viable circulating tumour cells (CTCs) from whole blood at high purity and with sufficient quality for functional assays. These requirements are not readily met by either label-based methods or size-only low-pass filters. Antibody labels can be specific yet miss phenotypically diverse CTCs, while size-based approaches may capture more broadly but suffer from leukocyte contamination. Here, we introduce a microfluidic band-stop filter that implements a size-selective transfer function, replacing a single threshold with an engineered peaked size-capture response. This is achieved by coupling hydrodynamic filtering with hydrodynamic trapping in a high-density array. Small cells follow streamlines that pass through trap apertures, intermediate-sized cells are admitted but retained by downstream constrictions, whereas larger cells occupy streamlines displaced from the channel wall and are hydrodynamically transported past the traps. As a result, only cells with diameters within the band-stop window are retained, while both smaller and larger cells pass. Using rigid microspheres, the device exhibits a canonical band-stop profile. Using cultured cell lines, capture efficiency peaks for CTC-like diameters and is suppressed for leukocyte-sized cells. Critically, the behaviour is preserved in undiluted, full haematocrit whole blood, where no leukocyte retention is observed and target-sized cancer cells are selectively enriched without fouling at capture efficiencies comparable to commercial systems. Trapped cells tolerate buffer exchange and on-chip drug exposure, where responses were concordant with matched off-chip culture. Cells are released on demand and expanded off-chip, confirming post-processing viability.

Indexed as

Cell SeparationLab-On-A-Chip DevicesMicrofluidic Analytical TechniquesNeoplastic Cells, CirculatingCell Line, TumorCell SurvivalEquipment DesignHumansHydrodynamics

Identifiers

PMID41948925
PMCPMC13058907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.